January 15, 2025 10:33 AM ESTUpdated 01:00 PM
News Briefing

Hinge Bio's $30M raise; Keros re­ports ad­di­tion­al is­sues in Phase 2 PAH tri­al

ENDPOINTS

Plus, news about In­flam­ma­some Ther­a­peu­tics, John­son & John­son and Ve­rastem:

Au­toim­mune dis­ease start­up nabs $30M: Hinge Bio

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

#JPM25 live blog day 3: Zealand aims to part­ner with a top-10 phar­ma; Lil­ly's 'pru­den­t' deal­mak­ing plans

On­col­o­gy biotech plots ex­pe­dit­ed ap­proval for bone can­cer drug af­ter Phase 2 win

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

BIO CEO plans to join FDA mod­ern­iza­tion ad­vi­so­ry board un­der Trump ad­min­is­tra­tion

A service from the Financial Times